11/06/2025 | Press release | Archived content
Quarterly report [Sections 13 or 15(d)]
Cover
|
Cover - shares |
9 Months Ended | |
|---|---|---|
|
Sep. 30, 2025 |
Nov. 06, 2025 |
|
| Cover [Abstract] | ||
| Document Type | 10-Q | |
| Amendment Flag | false | |
| Document Quarterly Report | true | |
| Document Transition Report | false | |
| Document Period End Date | Sep. 30, 2025 | |
| Document Fiscal Period Focus | Q3 | |
| Document Fiscal Year Focus | 2025 | |
| Current Fiscal Year End Date | --12-31 | |
| Entity File Number | 001-40023 | |
| Entity Registrant Name | GT BIOPHARMA, INC. | |
| Entity Central Index Key | 0000109657 | |
| Entity Tax Identification Number | 94-1620407 | |
| Entity Incorporation, State or Country Code | DE | |
| Entity Address, Address Line One | 505 Montgomery Street | |
| Entity Address, Address Line Two | 10th Floor | |
| Entity Address, City or Town | San Francisco | |
| Entity Address, State or Province | CA | |
| Entity Address, Postal Zip Code | 94111 | |
| City Area Code | 415 | |
| Local Phone Number | 919-4040 | |
| Title of 12(b) Security | Common Stock, $0.001 par value per share | |
| Trading Symbol | GTBP | |
| Security Exchange Name | NASDAQ | |
| Entity Current Reporting Status | Yes | |
| Entity Interactive Data Current | Yes | |
| Entity Filer Category | Non-accelerated Filer | |
| Entity Small Business | true | |
| Entity Emerging Growth Company | false | |
| Entity Shell Company | false | |
| Entity Common Stock, Shares Outstanding | 10,636,135 |